GMED Message Board - Msg: 1578852

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GMED

GMED 60.39

-0.5%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: kathleen who wrote (29)	6/12/1997 10:00:00 AM
From: Cong Cao	of 63

Lehman Bros. Starts Vical At Outperform >VICL Dow Jones News Service ~ June 10, 1997 ~ 9:40 am EST (MORE) DOW JONES NEWS 06-10-97 9:40 AM GeneMedicine, Vical -2: Lehman Sets Price Targets >GMED VICL NEW YORK (Dow Jones)--Lehman Brothers Inc. analyst Matthew Murray said he initiated coverage of GeneMedicine Inc. (GMED) at venture outperform and Vical Inc. (VICL) at outperform. Murray has 12-month share-price targets of 14 for GeneMedicine and 20 for Vical. GeneMedicine shares recently were up 1/4 at 8 1/2, and Vical shares were up 3/8 at 13 1/4. (END) DOW JONES NEWS 06-10-97 10:10 AM

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next